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To the Editor: Burns are the leading cause of non-natural death in 
infants and children aged under 5 years and the fourth major cause 
of accidental death in the 5 - 9-year age group,1 and more than 1 300 
children die annually from burns in South Africa. 
Since the treatment of burn wounds is among the most resource-
intensive of all paediatric trauma care,2 cost-effective treatment 
without compromising the clinical outcome is needed in the South 
African public health sector. 
Conventional care of partial-thickness burns often requires twice-
daily dressing changes to clean the wound and apply antimicrobial 
topical agents.3-5 These are often painful, time consuming and costly. 
New topical agents have been developed to target the increasing 
inefficiency of current agents, and the emergence of new and resistant 
organisms. Silver inactivates almost all bacteria and many fungi and 
extracellular viruses, and favourably influences mortality.4,6 However, 
silver-containing topical agents have become less effective,7 which 
negatively impacts on patient morbidity and septic mortality. 
To overcome resistance patterns, a topical nanocrystalline silver-
coated dressing containing Ag+, Ag0 and additional silver ions 
(Acticoat; Smith & Nephew) (NS) was developed. Studies6,8 confirmed 
its antibacterial spectrum and anti-inflammatory properties.9 In 
many burn centres NS is the first-line treatment of choice and has 
changed the management of small to moderate-sized burns from a 
largely inpatient to an outpatient process.10 However, the Department 
of Health has been reluctant to introduce this as a standard of care, as 
it costs more than other ‘traditional’ dressings.
A study comparing the effectiveness and cost of Silvazine (silver 
sulphadiazine and chlorhexidine digluconate cream) and NS  in the 
inpatient treatment of early burn wounds found that the average 
length of stay (LOS) in hospital was 40% shorter in the NS group, 
which also had a total cost saving of approximately 39%.11  Others 
have confirmed the antimicrobial properties12 and cost-effectiveness 
of NS.10 
In 2004 NS was introduced into the Red Cross War Memorial 
Children’s Hospital burns unit as the preferred treatment for 
moderate to major partial- and full-thickness burns. Because of the 
potential cost implications, an audit was performed to evaluate the 
cost effectiveness of NS compared with standard treatment methods.
Methods
We conducted a retrospective case study with 4 randomly selected 
paediatric burn patients, 1 from each of the body surface area groups 
20 - 29%, 30 - 39%, 40 - 49% and 50 - 59%. The cost associated 
with the use of NS dressings was calculated and compared with the 
projected costs of three previously standard burn wound treatment 
regimens. Only the treatment period during which patients received 
NS was costed. Outside of the NS treatment period the wounds 
were dressed with standard topical dressings, or were operated on. 
NS dressings were changed every 3 days based on their sustained 
and slow release of silver ions over 72 hours. Other topical agents 
would have required daily dressing changes to retain their maximal 
phamacodynamic and antiseptic efficacy, and the cost analysis was 
conducted according to this requirement. 
The cost analysis was performed using the ingredients approach, 
and was performed from the public sector perspective. Input costs 
reflect prices for the 2009 financial year and expressed in South 
African rands (ZAR).  
NS costs were calculated based on patients being taken to theatre 
for all dressing changes (standard practice in our unit for pain 
control, optimisation of sterility and ease of dressing changes for 
major burns). For standard burn therapy (SBT), we assumed that: (i) 
length of stay (LOS) for patients receiving SBT is 38% longer than for 
those receiving NS dressings;11 and (ii) patients receiving SBT require 
a minimum of a third of their dressing changes to be performed in 
theatre. 
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Treatment of paediatric burns with a nanocrystalline silver 
dressing compared with standard wound care in a burns unit:  
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Burns are a leading cause of non-natural death in South African 
infants and children. Conventional care of partial-thickness burns 
often requires painful, time consuming and costly twice-daily 
dressing changes to clean the wound and apply antimicrobial 
topical agents. A new topical nanocrystalline silver-coated (NS) 
dressing (Acticoat; Smith & Nephew) has been developed and is 
the first-line treatment of choice in many burn centres. However, 
because of its cost the Department of Health has been reluctant to 
introduce it as a standard of care.   
We retrospectively studied 4 randomly selected paediatric burn 
patients, calculating the cost associated with the use of NS dressings 
and comparing this with the projected costs of three previously 
standard burn wound treatment regimens. NS dressings were 
changed every 3 days based on their sustained and slow release of 
silver ions over 72 hours. Using NS clearly saved costs compared 
with the three other regimens. The demonstrated cost savings 
resulted primarily from the decreased number of dressings, and the 
presumed shorter hospital stay.
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The following resource categories were taken into consideration: 
(i) theatre fees as per the Uniform Patient Fee Schedule (UPFS) 
categories (UPFS 2009 Western Cape, revised June 2009, Annexure A, 
available from: http://www.doh.gov.za/programmes/upfs/docs/2009/
tariff_2009.pdf) ; (ii) ward fees as per the UPFS categories (UPFS 
2009 Western Cape); and (iii) medical supplies for topical burn care 
therapy as per Western Cape 2009 tender prices (or where not on 
tender, the price ex-manufacturer). All prices were inclusive of value-
added tax (VAT) at 14%. 
To effectively compare costs, the cost of three alternative treatment 
regimes for SBT for a burn area of 20×40 cm (the size that one 
portion of the product covers) was calculated (listed below). Since 
150 g of the topical agent is required to effectively cover a burned 
area of 20×40 cm, the costs were calculated as follows: (i) tulle gras 
(Jelonet; Smith & Nephew) + mupirocin + chlorhexidine, R134.95 
(i.e. R5.20 + R109.79 + R19.96); (ii) tulle gras + silver sulphadiazine, 
R17.90 (i.e. R5.20 + R12.70); and (iii) tulle gras + povidone iodine 
(5%), R9.94 (i.e. R5.20 + R4.74).
As the burns unit laboratory investigations and feeding of patients 
are standardised, these were not costed. Drugs, human resources, 
overhead, capital and indirect costs were not included. 
Results
The four patients studied were 2 boys and 2 girls, aged 1 - 12 years. 
Injuries were due to fire in 3 cases and hot water in 1, resulting in 
deep partial- to full-thickness burns of 21%, 45%, 33%, and 53% 
body surface area, respectively. Patient injury details and treatment 
duration are set out in Table I.
Table II and Fig. 1 compare actual theatre-based NS costs with 
calculated SBT costs, and show the cost saving when using NS 
compared with SBT.  
NS versus mupirocin/chlorhexidine mixture on a jelonet carrier: 
Average cost (R129 700) was calculated as 1.6 times the cost of using 
NS (R83 316) – average cost saving of R46 383 per patient. 
NS versus silver sulphadiazine 1% cream on a jelonet carrier: 
Average cost (R110 341) was calculated as 1.3 times the cost of using 
NS (R83 316) – average cost saving of R27 024 per patient. 
NS versus povidone iodine 5% cream on a jelonet carrier: 
Average cost (R108 999) was calculated as being 1.3 times the cost 
of using NS (R83 316) – average cost saving of R25 683 per patient. 
In terms of safety, no patient developed any local or systemic 
reaction to NS.
Discussion
The care of children with burns is a resource-intensive process posing 
particular challenges in terms of pain control, frequent cleansing of 
wounds and the application of topical antibacterial agents to avoid 
infection. 
Many topical agents are used for burn care. They are not universally 
effective, and differ in their ability to penetrate an eschar and in 
their bio- and antibacterial activity and side-effects.3 They may be 
combined to enhance their effects. A single agent that consolidates 
most of the desired activities of a topical agent would be beneficial 
in terms of frequency and ease of application, be effective, not 
have undesirable side-effects, and be cost-effective  and reduce the 
Table I. Injury and treatment duration
NS actual SBT assumption
Case Burn size (%) Burn nature
Period NS used 
(days)
Dressing 
changes in 
theatre
Period SBT 
used (days)
Dressing 
changes in 
theatre
1 21 Full and partial thickness 29 6 40 13
2 45 Deep partial to full thickness 17 5 23 8
3 33 Superficial to deep partial thickness 16 4 22 7
4 53 Intermediate to full thickness 25 7 35 11
NS = nanocrystalline silver; SBT = standard burn therapy.
Table II. Calculated costs of the various topical agents compared with NS showing cost savings for NS compared with each agent
Case
Composite cost  
NS
Composite cost 
mupirocin
Cost saving NS v. 
mupirocin
Composite cost 
sulphadiazine
Cost saving NS v. 
sulphadiazine
Composite cost 
povidone
Cost saving NS v. 
povidone
1 R97 404.96 R181 095.88 R83 690.92 R172 288.34 R74 883.38 R171 688.24 R74 283.28 
2 R79 131.88 R111 035.48 R31 903.60 R90 441.41 R11 309.53 R89 059.70 R9 927.82 
3 R45 196.08 R65 155.43 R19 959.35 R48 362.78 R3 166.70 R47 220.51 R2 024.43 
4 R111 532.70 R161 513.72 R49 081.02 R130 270.71 R18 738.01 R128 027.13 R16 494.43 
Mean R83 316.41 R129 700.13 R46 383.72 R110 340.81 R27 024.41 R108 998.89 R25 682.49 
Fig. 1. Comparative costs of the dressing alternatives in all 4 patients.
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development of resistant patterns. NS dressings combines most 
of these beneficial effects in a single dressing.11 The dressing was 
approved by the US Food and Drug Administration as a barrier 
dressing to prevent and treat burn wound sepsis.9 Silver (Ag0) also 
has anti-inflammatory activity independent of antimicrobial action, 
induces apoptosis in inflammatory cells, and suppresses matrix 
metalloproteinase activity and pro-inflammatory cytokines.9  Because 
of these factors, commercial availability and increasing use of NS, a 
practical cost assessment had to be made.
Using NS clearly saves costs compared with three other regimens 
of standard burn therapy. A major advantage of this dressing is that 
it only needs to be changed every 3 days. The need in ‘standard’ burn 
care for daily dressing changes increases the burden of burn wound 
care and pain, nosocomial wound infection risk, costs of care and risk 
of damaging the newly formed epithelial skin layer. 
The demonstrated cost savings resulted primarily from the 
decreased number of dressings, and the presumed shorter hospital 
stay. Likely further cost drivers include the increased use of anti-
infectives with SBT,11 and increased human resource costs; however, 
these resource categories were not studied. NS is not recommended 
as a dressing for donor sites or for small superficial burns that can be 
treated effectively with standard treatment modalities.13
While acknowledging that this is a very small selection of patients 
and larger numbers are required for more accurate comparison, 
this study is an example of how management that is perceived to be 
prohibitively expensive for the state health service may be more cost 
effective and clinically appropriate than originally anticipated. 
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